B.Sc. University of Toronto’s Erindale College
Hank Klakurka has over 40 years in the pharmaceutical industry and has extensive experience in both branded and generic pharmaceuticals. He played a key role in the sale of Merck’s generics division, at the end of 2007, to Pittsburgh-based Mylan Labs for US$6.7B, representing a near-record multiple for the sector. He grew the Merck Generics business from approximately €900M to €1.8B since joining the company in 2001 as head of its Americas Region. He was promoted to CEO of the global group in 2003. The Merck Generics Group was the third largest global generics pharmaceutical company doing business in over 90 countries with a staff of 5000+ employees located in more than 35 countries around the world.
Prior to joining Merck, Mr. Klakurka held progressively more resposible positions with several other major pharmaceutical companies including Astra, Schering-Plough, Johnson & Johnson and Apotex.
Some of Mr. Klakurk’s former roles include:
-Former CEO, Merck Generics Group, Division of Merck KGaA, Germany
-Director, Soho Global Health, Indonesia
-Director, Blue-Zone Technologies Ltd., Toronto, Canada
-Operating Partner, Quadria Capital Investment Management, Singapore, India
-Pharma and Non-Pharma Advisor, several private equity firms, USA, EU, SEA
-Pharma Industry Consultant
